This Week in CRC Research — July 12, 2026
Weekly colorectal cancer research intelligence
dmmr
A collection of 120 issues
RAS and BRAF status in MSI-H/dMMR metastatic CRC
Skip to content
The CRC Digest
RAS and BRAF status in MSI-H/dMMR metastatic CRC
New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
CRC Research Update — July 10, 2026
Today's colorectal cancer research highlights
Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1
Skip to content
The CRC Digest
Stage III/IV MSI-H CRC Shows Reduced T-Cell Infiltration and Elevated IDO1
Analysis of 217 patients with dMMR/MSI-H colorectal cancer found that stage III/IV tumors had reduced immune infiltration and upregulated epithelial IDO1 expression compared to stage I/II, suggesting immune evasion
CRC Research Update — July 08, 2026
Today's colorectal cancer research highlights
Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer
Skip to content
The CRC Digest
Microbiota influences immunotherapy efficacy in MSI-H colorectal cancer
Immune checkpoint inhibitors benefit patients with mismatch repair-deficient/microsatellite instability-high colorectal cancer, and gut microbiota appears to play a key role in treatment response. (Life Sciences)
This content is informational only and does not constitute medical
CRC Research Finding
Skip to content
The CRC Digest
◇ Review highlights gut microbiota's role in immunotherapy response, especially for MSI-H tumors
A comprehensive review evaluates how gut microbiota and microbial metabolites influence colorectal cancer development, the tumor microenvironment, and immunotherapy responses, with emphasis on strategies for proficient mismatch repair/microsatellite-stable tumors
CRC Research Update — July 03, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
◇ Mismatch repair-deficient CRC with bowel obstruction shows excellent response to immunotherapy
A case series reports that patients with mismatch repair-deficient (dMMR) colorectal cancer presenting with bowel obstruction achieved excellent responses to immunotherapy. (Annals of Coloproctology)
This content is informational only and does not constitute
CRC Research Update — July 02, 2026
Today's colorectal cancer research highlights